Publications 2024

Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352

Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720

Bjørgo E, Fagereng GL, Russnes HG, Smeland S, Taskén K, Helland Å (2024)
Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare
Acta Oncol, 63, 487-490
DOI 10.2340/1651-226X.2024.24954, PubMed 38910311

Edsjö A, Russnes HG, Lehtiö J, Tamborero D, Hovig E, Stenzinger A, Rosenquist R, PCM4EU consortium (2024)
High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond
J Intern Med, 295 (6), 785-803
DOI 10.1111/joim.13785, PubMed 38698538

Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K (2024)
[Raising the quality of cancer treatment]
Tidsskr Nor Laegeforen, 144 (1)
DOI 10.4045/tidsskr.23.0740, PubMed 38258713

Niehusmann P, Leske H, Nygaard V, Russnes HG, Zhao S, Latysheva A, Straume Wiig U, Stankuniene B, Ulvmoen A (2024)
Desmoplastic non-infantile ganglioglioma mimicking diffuse leptomeningeal glioneuronal tumor: precision diagnostics and therapeutic implications
Acta Oncol, 63, 392-394
DOI 10.2340/1651-226X.2024.31720, PubMed 38779936

Ohnstad HO, Blix ES, Akslen LA, Gilje B, Raj SX, Skjerven H, Borgen E, Janssen EAM, Mortensen E, Brekke MB, Falk RS, Schlichting E, Boge B, Songe-Møller S, Olsson P, Heie A, Mannsåker B, Vestlid MA, Kursetgjerde T, Gravdehaug B, Suhrke P, Sanchez E, Bublevic J, Røe OD, Geitvik GA et al. (2024)
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499

Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H et al. (2024)
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
Acta Oncol, 63, 385-391
DOI 10.2340/1651-226X.2024.34791, PubMed 38779910

van de Haar J, Roepman P, Andre F, Balmaña J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchiò C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J (2024)
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
Ann Oncol, 35 (11), 954-967
DOI 10.1016/j.annonc.2024.06.018, PubMed 39112111

Publications 2023

Gjelberg HK, Helgeland L, Liseth K, Micci F, Sandnes M, Russnes HG, Reikvam H (2023)
Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature
Curr Oncol, 30 (11), 10007-10018
DOI 10.3390/curroncol30110727, PubMed 37999147

Stashko C, Hayward MK, Northey JJ, Pearson N, Ironside AJ, Lakins JN, Oria R, Goyette MA, Mayo L, Russnes HG, Hwang ES, Kutys ML, Polyak K, Weaver VM (2023)
A convolutional neural network STIFMap reveals associations between stromal stiffness and EMT in breast cancer
Nat Commun, 14 (1), 3561
DOI 10.1038/s41467-023-39085-1, PubMed 37322009

Publications 2022

Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Mælandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio F (2022)
ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
JCO Precis Oncol, 6 (1), e2200015
DOI 10.1200/PO.22.00015, PubMed 35476549

Flobak Å, Skånland SS, Hovig E, Taskén K, Russnes HG (2022)
Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models
Trends Pharmacol Sci, 43 (11), 973-985
DOI 10.1016/j.tips.2022.08.009, PubMed 36163057

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045

Hjerkind KV, Johansson ALV, Trewin CB, Russnes HG, Ursin G (2022)
Incidence of breast cancer subtypes in immigrant and non-immigrant women in Norway
Breast Cancer Res, 24 (1), 4
DOI 10.1186/s13058-021-01498-5, PubMed 35012613

Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
Acta Oncol, 61 (8), 955-962
DOI 10.1080/0284186X.2022.2098053, PubMed 35943168

Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103

Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529

Publications 2021

Bjaanæs MM, Nilsen G, Halvorsen AR, Russnes HG, Solberg S, Jørgensen L, Brustugun OT, Lingjærde OC, Helland Å (2021)
Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors
BMC Cancer, 21 (1), 1089
DOI 10.1186/s12885-021-08811-7, PubMed 34625038

Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K (2021)
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
JCI Insight, 6 (11)
DOI 10.1172/jci.insight.147617, PubMed 33886505

Nobre AR, Risson E, Singh DK, Di Martino JS, Cheung JF, Wang J, Johnson J, Russnes HG, Bravo-Cordero JJ, Birbrair A, Naume B, Azhar M, Frenette PS, Aguirre-Ghiso JA (2021)
Bone marrow NG2⁺/Nestin⁺ mesenchymal stem cells drive DTC dormancy via TGFβ2
Nat Cancer, 2 (3), 327-339
DOI 10.1038/s43018-021-00179-8, PubMed 34993493

Rye IH, Huse K, Josefsson SE, Kildal W, Danielsen HE, Schlichting E, Garred Ø, Riis ML, Osbreac, Lingjaerde OC, Myklebust JH, Russnes HG (2021)
Breast cancer metastasis: immune profiling of lymph nodes reveals exhaustion of effector T cells and immunosuppression
Mol Oncol, 16 (1), 88-103
DOI 10.1002/1878-0261.13047, PubMed 34165864

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2020

Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163

Pladsen AV, Nilsen G, Rueda OM, Aure MR, Borgan Ø, Liestøl K, Vitelli V, Frigessi A, Langerød A, Mathelier A, OSBREAC, Engebråten O, Kristensen V, Wedge DC, Van Loo P, Caldas C, Børresen-Dale AL, Russnes HG, Lingjærde OC (2020)
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091

Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873

Russnes HG (2020)
Clinical trials in the era of precision cancer medicine - for the few or for the many?
Acta Oncol, 59 (7), 731-732
DOI 10.1080/0284186X.2020.1777582, PubMed 32579040

Publications 2019

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P (2019)
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 10 (1), 525
DOI 10.1038/s41467-019-08512-7, PubMed 30692535

Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
Breast cancer quantitative proteome and proteogenomic landscape
Nat Commun, 10 (1), 1600
DOI 10.1038/s41467-019-09018-y, PubMed 30962452

Kraby MR, Opdahl S, Russnes HG, Bofin AM (2019)
Microvessel density in breast cancer: the impact of field area on prognostic informativeness
J Clin Pathol, 72 (4), 304-310
DOI 10.1136/jclinpath-2018-205536, PubMed 30630872

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006

Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Publications 2018

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P (2018)
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 9 (1), 5397
DOI 10.1038/s41467-018-07842-2, PubMed 30559362

Ellingjord-Dale M, Vos L, Vik Hjerkind K, Hjartåker A, Russnes HG, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G (2018)
Number of Risky Lifestyle Behaviors and Breast Cancer Risk
JNCI Cancer Spectr, 2 (3), pky030
DOI 10.1093/jncics/pky030, PubMed 31360858

Głodzik D, Purdie C, Rye IH, Simpson PT, Staaf J, Span PN, Russnes HG, Nik-Zainal S (2018)
Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers
Ann Oncol, 29 (11), 2223-2231
DOI 10.1093/annonc/mdy404, PubMed 30252041

Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG (2018)
Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors
Mol Oncol, 12 (11), 1838-1855
DOI 10.1002/1878-0261.12375, PubMed 30133130

Publications 2017

Alves CP, Dey-Guha I, Kabraji S, Yeh AC, Talele NP, Solé X, Chowdhury J, Mino-Kenudson M, Loda M, Sgroi D, Borresen-Dale AL, Russnes HG, Ross KN, Ramaswamy S (2017)
AKT1^low Quiescent Cancer Cells Promote Solid Tumor Growth
Mol Cancer Ther, 17 (1), 254-263
DOI 10.1158/1535-7163.MCT-16-0868, PubMed 29054988

Cheng J, Demeulemeester J, Wedge DC, Vollan HKM, Pitt JJ, Russnes HG, Pandey BP, Nilsen G, Nord S, Bignell GR, White KP, Børresen-Dale AL, Campbell PJ, Kristensen VN, Stratton MR, Lingjærde OC, Moreau Y, Van Loo P (2017)
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors
Nat Commun, 8 (1), 1221
DOI 10.1038/s41467-017-01355-0, PubMed 29089486

Ellingjord-Dale M, Vos L, Hjerkind KV, Hjartåker A, Russnes HG, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G (2017)
Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program
Cancer Epidemiol Biomarkers Prev, 26 (12), 1736-1744
DOI 10.1158/1055-9965.EPI-17-0611, PubMed 28877889

Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell CH, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, Bobolis K et al. (2017)
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
Cancer Discov, 7 (10), 1098-1115
DOI 10.1158/2159-8290.CD-17-0222, PubMed 28652380

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B (2017)
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120
DOI 10.1186/s13058-017-0911-9, PubMed 29137653

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742

Russnes HG, Lingjærde OC, Børresen-Dale AL, Caldas C (2017)
Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters
Am J Pathol, 187 (10), 2152-2162
DOI 10.1016/j.ajpath.2017.04.022, PubMed 28733194

Publications 2015

Potapenko IO, Lüders T, Russnes HG, Helland Å, Sørlie T, Kristensen VN, Nord S, Lingjærde OC, Børresen-Dale AL, Haakensen VD (2015)
Glycan-related gene expression signatures in breast cancer subtypes; relation to survival
Mol Oncol, 9 (4), 861-76
DOI 10.1016/j.molonc.2014.12.013, PubMed 25655580

Publications 2014

Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K (2014)
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity
Cell Rep, 6 (3), 514-27
DOI 10.1016/j.celrep.2013.12.041, PubMed 24462293

Kristensen VN, Lingjærde OC, Russnes HG, Vollan HK, Frigessi A, Børresen-Dale AL (2014)
Principles and methods of integrative genomic analyses in cancer
Nat Rev Cancer, 14 (5), 299-313
DOI 10.1038/nrc3721, PubMed 24759209

Russnes HG, Caldas C (2014)
eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN
EMBO Mol Med, 6 (12), 1512-4
DOI 10.15252/emmm.201404683, PubMed 25471453

Russnes HG, Lønning PE, Børresen-Dale AL, Lingjærde OC (2014)
The multitude of molecular analyses in cancer: the opening of Pandora’s box
Genome Biol, 15 (9), 447
DOI 10.1186/s13059-014-0447-6, PubMed 25316146

Rye IH, Lundin P, Månér S, Fjelldal R, Naume B, Wigler M, Hicks J, Børresen-Dale AL, Zetterberg A, Russnes HG (2014)
Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors
Genes Chromosomes Cancer, 54 (4), 235-48
DOI 10.1002/gcc.22237, PubMed 25546585

Sternemalm J, Russnes HG, Zhao X, Risberg B, Nord S, Caldas C, Børresen-Dale AL, Stokke T, Patzke S (2014)
Nuclear CSPP1 expression defined subtypes of basal-like breast cancer
Br J Cancer, 111 (2), 326-38
DOI 10.1038/bjc.2014.297, PubMed 24901235

Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F (2014)
GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images
Genome Biol, 15 (8), 442
DOI 10.1186/s13059-014-0442-y, PubMed 25168174

Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, Sun H, Kim JH, Carver K, Zucca M, Feng J, Almendro V, Bessarabova M, Rueda OM, Nikolsky Y, Caldas C, Liu XS, Polyak K (2014)
JARID1B is a luminal lineage-driving oncogene in breast cancer
Cancer Cell, 25 (6), 762-77
DOI 10.1016/j.ccr.2014.04.024, PubMed 24937458

Zhao X, Rødland EA, Sørlie T, Vollan HK, Russnes HG, Kristensen VN, Lingjærde OC, Børresen-Dale AL (2014)
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status
BMC Cancer, 14, 211
DOI 10.1186/1471-2407-14-211, PubMed 24645668

Publications 2013

Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, Engel P, Costamagna D, Fernandez PL, Gascón P, Almendro V (2013)
Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer
Cancer Res, 73 (21), 6424-34
DOI 10.1158/0008-5472.CAN-12-4573, PubMed 24030979

Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J et al. (2013)
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer
Sci Transl Med, 5 (181), 181re1
DOI 10.1126/scitranslmed.3006112, PubMed 23596205

Publications 2012

Synnestvedt M, Borgen E, Russnes HG, Kumar NT, Schlichting E, Giercksky KE, Kåresen R, Nesland JM, Naume B (2012)
Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy
Acta Oncol, 52 (1), 91-101
DOI 10.3109/0284186X.2012.713508, PubMed 22934555

Publications 2011

Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL (2011)
miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
PLoS One, 6 (2), e16915
DOI 10.1371/journal.pone.0016915, PubMed 21364938

Molloy TJ, Bosma AJ, Baumbusch LO, Synnestvedt M, Borgen E, Russnes HG, Schlichting E, van't Veer LJ, Naume B (2011)
The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients
Breast Cancer Res, 13 (3), R61
DOI 10.1186/bcr2898, PubMed 21672237

Russnes HG, Kuligina ESh, Suspitsin EN, Voskresenskiy DA, Jordanova ES, Cornelisse CJ, Borresen-Dale AL, Imyanitov EN (2011)
Paired distribution of molecular subtypes in bilateral breast carcinomas
Cancer Genet, 204 (2), 96-102
DOI 10.1016/j.cancergencyto.2010.09.012, PubMed 21504707

Russnes HG, Navin N, Hicks J, Borresen-Dale AL (2011)
Insight into the heterogeneity of breast cancer through next-generation sequencing
J Clin Invest, 121 (10), 3810-8
DOI 10.1172/JCI57088, PubMed 21965338

Publications 2010

Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalgi R, Tarcic G, Bossel N, Zeisel A, Amit I, Zwang Y, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano S, Blandino G, Børresen-Dale AL, Pilpel Y, Yakhini Z, Segal E, Yarden Y (2010)
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors
Sci Signal, 3 (124), ra43
DOI 10.1126/scisignal.2000876, PubMed 20516477

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Stromberg M, Wiedswang G, Kvalheim G, Karesen R, Nesland JM, Borresen-Dale AL, Sorlie T (2010)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (vol 1, pg 160, 2007)
Mol. Oncol., 4 (2), 169
DOI 10.1016/j.molonc.2010.01.003

Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL, FEMME Consortium (2010)
Triple-negative breast cancer: present challenges and new perspectives
Mol Oncol, 4 (3), 209-29
DOI 10.1016/j.molonc.2010.04.006, PubMed 20537966

Russnes HEG (2010)
Molecular classification of breast carcinomas
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 979, 1 b. (flere pag.)
BIBSYS 101481047, ISBN 978-82-8072-585-1

Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL (2010)
Genomic architecture characterizes tumor progression paths and fate in breast cancer patients
Sci Transl Med, 2 (38), 38ra47
DOI 10.1126/scitranslmed.3000611, PubMed 20592421

Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Børresen-Dale AL, Kristensen VN (2010)
Allele-specific copy number analysis of tumors
Proc Natl Acad Sci U S A, 107 (39), 16910-5
DOI 10.1073/pnas.1009843107, PubMed 20837533

Publications 2009

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161

Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE et al. (2009)
Complex landscapes of somatic rearrangement in human breast cancer genomes
Nature, 462 (7276), 1005-10
DOI 10.1038/nature08645, PubMed 20033038

Publications 2008

Bergamaschi A, Tagliabue E, Sørlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, Børresen-Dale AL (2008)
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
J Pathol, 214 (3), 357-67
DOI 10.1002/path.2278, PubMed 18044827

Greenberg JA, Somme S, Russnes HE, Durbin AD, Malkin D (2008)
The estrogen receptor pathway in rhabdomyosarcoma: a role for estrogen receptor-beta in proliferation and response to the antiestrogen 4'OH-tamoxifen
Cancer Res, 68 (9), 3476-85
DOI 10.1158/0008-5472.CAN-07-3046, PubMed 18451176

Publications 2007

Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, Nesland JM, Børresen-Dale AL, Sørlie T (2007)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer
Mol Oncol, 1 (2), 160-71
DOI 10.1016/j.molonc.2007.03.004, PubMed 19383292

Publications 2000

Giercksky HE, Nesland JM (2000)
[Microdissection--an important tool in molecular biology]
Tidsskr Nor Laegeforen, 120 (5), 598-600
PubMed 10833921

Publications 1997

Giercksky HE, Thorstensen L, Qvist H, Nesland JM, Lothe RA (1997)
Comparison of genetic changes in frozen biopsies and microdissected archival material from the same colorectal liver metastases
Diagn Mol Pathol, 6 (6), 318-25
DOI 10.1097/00019606-199712000-00003, PubMed 9559291